Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 479 or AMG 102 plus platinum-etoposide for first-line extensive-stage small cell lung cancer
NL-OMON33131Phase 2Active, not recruiting
- Sponsor
- Amgen
- Start
- Feb 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of ganitumab and rilotumumab in small cell lung cancer (SCLC) (7 arms), sponsored by Amgen. Primary endpoints: Incidence of dose-limiting toxicity and Overall survival. Started Feb 2010; status: active, not recruiting.
02
Drugs
ganitumabrilotumumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NL-OMON33131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33131.